Morten Nissen is a partner and co-head of the international Competition & EU group at Bird & Bird, based in Copenhagen. He also leads the Competition & EU team in Denmark. He has a particular focus on applying competition & EU law as a tool to achieve specific and measurable business objectives for clients. Competition authorities act differently in different countries. He has solid international experience and an outlook based on working for more than 12 years as a lawyer based in Brussels, which includes doing a number of fascinating competition cases in many countries across Europe as well as Asia. This first-hand experience helps him better navigate cases to obtain results that make a difference. His prime focus is on state aid, competition restricting agreements, and abuse of dominance. I have made numerous EU and national merger control notifications, and he is always focused on optimising the business outcome and delivering competitive advantage. He is proud to say he has been involved in a high number of cases that made new case law. His sector experience is particularly strong in the pharmaceutical, copyright, media, IT, telecoms, passenger transport and international payment systems sectors. Over the years, he has represented clients in a large number of legal procedures before the EU Court of Justice in Luxembourg. Amongst these, he has won four appeal cases against the EU Commission, including a state aid case before the Grand Chamber of the EU court of justice which ultimately led to the EU Commission’s Legal Service turning around and choosing him to represent the Commission in a number of other state aid cases. Until 2012, he was a partner in the Brussels office. He left Bird & Bird to start a pharmaceutical business and other start-ups. After this, he was Of Counsel at a leading Danish firm, before finding his way home to Bird & Bird in 2018. At Bird & Bird, he benefits from a truly international set-up and he has a personal network that allows him to know exactly who is well placed to handle a particular case in one of many offices around the word. It particularly allows him to pull in points of view from a high-quality pool of 65 competition lawyers around the world. He is a member of the World Competition, Law and Economics Journals Advisory Board (Kluwer) and co-authored ’Guide to EU Pharmaceutical Regulatory Law’ (Kluwer).